Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This multidisciplinary work shows the feasibility of replacing the fetal pulmonary valve with a percutaneous, transcatheter, fully biodegradable tissue-engineered heart valve (TEHV), which was studied in vitro through accelerated degradation, mechanical, and hemodynamic testing and in vivo by implantation into a fetal lamb. The TEHV exhibited only trivial stenosis and regurgitation in vitro and no stenosis in vivo by echocardiogram. Following implantation, the fetus matured and was delivered at term. Replacing a stenotic fetal valve with a functional TEHV has the potential to interrupt the development of single-ventricle heart disease by restoring proper flow through the heart.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452327 | PMC |
| http://dx.doi.org/10.1016/j.jacbts.2020.06.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of Transcatheter or Surgical Treatment of Severe Aortic Stenosis in Patients With Coronary Artery Disease.
Struct Heart
September 2025
Heart and Vascular Institute, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
•Outcomes of surgical aortic valve replacement + coronary artery bypass grafting vs. transcatheter aortic valve replacement (TAVR) + percutaneous coronary intervention (PCI) in severe aortic stenosis and coronary artery disease patients.•TAVR + PCI had lower 30-day acute kidney injury and bleeding, similar 2-year mortality/stroke.
View Article and Find Full Text PDFSpanish cardiac catheterization and coronary intervention registry. 34 official report of the Interventional Cardiology Association of the Spanish Society of Cardiology (1990-2024).
Rev Esp Cardiol (Engl Ed)
September 2025
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, España; Servicio de Cardiología, Hospital Clínico de Santiago de Compostela, Santiago de Compostela, España.
Introduction And Objectives: This report presents the 2024 activity data from the Interventional Cardiology Association of the Spanish Society of Cardiology (ACI-SEC).
Methods: All interventional cardiology laboratories in Spain were invited to complete an online survey. Data analysis was conducted by an external company and then reviewed and presented by the ACI-SEC board.
The evolution of concomitant mitral regurgitation in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: a prospective multi-center China-DVD2 cohort study.
Cardiol J
September 2025
Department of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Background: Severe aortic stenosis (AS) often coexists with mitral regurgitation (MR). This study evaluated the significant evolution of MR in patients undergoing transcatheter aortic valve replacement (TAVR) for AS.
Methods: This multi-center China Degenerative Valve Disease II Cohort (China-DVD2) Study enrolled patients undergoing TAVR for AS from January 2020 to October 2023.
Transcatheter atrial septal defects and patent foramen ovale closure: Medicare utilization and reimbursements.
World J Methodol
December 2025
Department of Cardiology, University of Miami-Miller School of Medicine, Miami, FL 33136, United States.
Background: The Food and Drug Administration has approved percutaneous atrial septal defect (ASD) and patent foramen ovale (PFO) closure devices for hemodynamically significant interatrial shunts, paradoxical emboli including stroke, and decompression sickness. We aimed to study the trends in utilization and reimbursements of transcatheter ASD/PFO closure devices.
Aim: To analyze trends in utilization and Medicare reimbursements for transcatheter ASD/PFO closure procedures from 2013 to 2022.
Feasibility, Efficacy, and Safety of the Mitral Annulo-TRIpsy in eXtreme Risk Patients.
Struct Heart
August 2025
Gagnon Cardiovascular Institute, Atlantic Health System, Morristown, New Jersey, United States.
Background: Severe calcific mitral stenosis is common and therapeutically challenging. Intravascular lithotripsy (IVL) can facilitate percutaneous balloon mitral valvuloplasty in patients not amenable to conventional therapies. We describe a modified technique using larger IVL balloons to ensure maximal annular contact and delivery of ultrasonic shockwaves to restore mitral leaflet pliability and reduce transvalvular gradients without the need for noncompliant valvuloplasty balloons.
View Article and Find Full Text PDF